Pfizer registers Phase 3 trial of atirmociclib plus giredestrant in ER+ HER2- early breast cancer
The study plans to enroll 3800 participants and randomize them 1:1 to receive atirmociclib plus giredestrant or placebo plus giredestrant. It is scheduled to begin on December 1, 2026, with a primary completion date of April 13, 2032.
Primary source
ClinicalTrials.gov registry record, October 22, 2026
A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
Read the source: A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation